TransMedics Group, Inc. (TMDX) Total Return CAGR:-36.48%(TTM)
Over the latest trailing 12-month period, TransMedics Group, Inc. (TMDX)'s total return cagr is -36.48%. The comparable SPY value is +26.75%. Year-to-date total return is -35.23%. Total return includes price appreciation and reinvested dividends.
Over longer horizons, TransMedics Group, Inc.'s Total Return CAGR averages 0.07% over 3 years and 21.48% over 5 years. Total return includes dividends reinvested. The total return CAGR includes both price appreciation and dividends reinvested. This gives a more complete picture of TransMedics Group, Inc.'s investment performance.
TMDX Total Return CAGR Chart
TransMedics Group, Inc. (TMDX)
TMDX Quarterly Total Return (YoY)
Total Return Index growth vs the same quarter one year earlier, last 20 quarters.
TMDX Total Return CAGR History
| Year | Start Total Return | End Total Return | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2026 | 544.05 | 352.37 | -191.68 | -35.23% | -35.23% |
| 2025 | 278.85 | 544.05 | +265.21 | +95.11% | +95.11% |
| 2024 | 353.00 | 278.85 | -74.15 | -21.01% | -21.01% |
| 2023 | 276.03 | 353.00 | +76.97 | +27.88% | +27.88% |
| 2022 | 85.69 | 276.03 | +190.34 | +222.13% | +222.13% |
| 2021 | 89.00 | 85.69 | -3.31 | -3.72% | -3.72% |
| 2020 | 85.02 | 89.00 | +3.98 | +4.68% | +4.68% |
Quarterly Total Return: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q2 2026 | 352 | -16.5% | -41.2% |
| Q1 2026 | 422 | -22.5% | +40.2% |
| Q4 2025 | 544 | +8.4% | +95.1% |
| Q3 2025 | 502 | -16.3% | -28.5% |
| Q2 2025 | 599 | +99.2% | -11.0% |
| Q1 2025 | 301 | +7.9% | -9.2% |
| Q4 2024 | 279 | -60.3% | -21.0% |
| Q3 2024 | 702 | +4.2% | +176.6% |
| Q2 2024 | 674 | +103.2% | +79.4% |
| Q1 2024 | 331 | -6.1% | -2.1% |
| Q4 2023 | 353 | +39.0% | +27.9% |
| Q3 2023 | 254 | -32.4% | +33.8% |
| Q2 2023 | 376 | +10.9% | +166.6% |
| Q1 2023 | 339 | +22.7% | +193.0% |
| Q4 2022 | 276 | +45.4% | +217.3% |
| Q3 2022 | 190 | +34.7% | +33.5% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About TransMedics Group, Inc.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Waleed H. Hassanein